An Open Label Extension Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Trial Profile

An Open Label Extension Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 14 May 2015

At a glance

  • Drugs Mifepristone (Primary)
  • Indications Cushing syndrome
  • Focus Adverse reactions; Registrational
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 14 May 2015 According to a Corcept Therapeutics media release, data from this study was presented in the posters at the 24th annual American Association of Clinical Endocrinologists in May 2015.
    • 05 Mar 2015 According to a Corcept Therapeutics media release, data from this study were presented at the 97th annual Endocrine Society Meeting (ENDO 2015).
    • 01 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top